TY - JOUR JO - EuroIntervention TI - Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial AB - <p class="text-1er-paragraph"><span class="abstracts-titres">Aims:</span> Drug-eluting stents (DES) were first used on-label - in simple patients with low clinical risk and easily accessible lesions. Currently, DES are increasingly used off-label - in com AU - Sen Hanim AU - Lam Ming Kai AU - Tandjung Kenneth AU - Basalus Mounir W.Z. AU - de Man Frits H.A.F. AU - Louwerenburg Johannes Hans W. AU - Stoel Martin G. AU - van Houwelingen K. Gert AU - Löwik Marije M. AU - Linssen Gerard C.M. AU - Said Salah A.M. AU - Nienhuis Mark B. AU - Verhorst Patrick M.J. AU - van der Palen Job AU - von Birgelen Clemens VL - 10 IS - 6 Y1 - 20/10/2014 Y1 - 2014 DOI - 10.4244/EIJV10I6A117 SP - 664 EP - 671 KW - complex patients KW - clinical research KW - off-label KW - percutaneous coronary intervention KW - randomised controlled trial KW - twente trial PB - Europa Digital & Publishing SE - CORONARY INTERVENTIONS UR - https://eurointervention.pcronline.com/article/clinical-outcome-following-second-generation-drug-eluting-stent-use-for-off-label-versus-on-label-indications-insights-from-the-two-year-outcome-of-the-twente-trial SN - 1774-024X ER -